We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension.
- Authors
Plaunt, Adam J.; Islam, Sadikul; Macaluso, Tony; Gauani, Helena; Baker, Thomas; Chun, Donald; Viramontes, Veronica; Chang, Christina; Corboz, Michel R.; Chapman, Richard W.; Li, Zhili; Cipolla, David C.; Perkins, Walter R.; Malinin, Vladimir S.
- Abstract
Treprostinil palmitil (TP) is a prodrug of treprostinil (TRE), a pulmonary vasodilator that has been previously formulated for inhaled administration via a nebulizer. TP demonstrates a sustained presence in the lungs with reduced systemic exposure and prolonged inhibition of hypoxia-induced pulmonary vasoconstriction in vivo. Here, we report on re-formulation efforts to develop a more convenient solution-based metered-dose inhaler (MDI) formulation of TP, a treprostinil palmitil inhalation aerosol (TPIA) that matches the pharmacokinetic (PK) and efficacy profile of a nebulized TP formulation, treprostinil palmitil inhalation suspension (TPIS). MDI canisters were manufactured using a two-stage filling method. Aerosol performance, formulation solubility, and chemical stability assays were utilized for in vitro evaluation. For in vivo studies, TPIA formulations were delivered to rodents using an inhalation tower modified for MDI delivery. Using an iterative process involving evaluation of formulation performance in vitro (TP and excipient solubility, chemical stability, physical stability, and aerosol properties) and confirmatory testing in vivo (rat PK and efficacy, guinea pig cough), a promising formulation was identified. The optimized formulation, TPIA-W, demonstrates uniform in vitro drug delivery, a PK profile suitable for a once-daily administration, efficacy lasting at least 12 h in a hypoxic challenge model, and a significantly higher cough threshold than the parent drug treprostinil.
- Subjects
PULMONARY hypertension; INVESTIGATIONAL therapies; AEROSOLS; METERED-dose inhalers; CHEMICAL stability; NITROIMIDAZOLES; DRUG solubility; BONE morphogenetic protein receptors
- Publication
International Journal of Molecular Sciences, 2021, Vol 22, Issue 2, p548
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms22020548